Erythropoietin News and Research RSS Feed - Erythropoietin News and Research

Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.
Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis. [More]
Erythropoietin may promote cancer cell proliferation and survival

Erythropoietin may promote cancer cell proliferation and survival

In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide. [More]

Study shows beneficial effects of normobaric oxygen on cerebral ischemic injury

Normobaric oxygen has the rapid and non-invasive characteristics and may have therapeutic effects on ischemic/hypoxic disease. [More]

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs. The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem. [More]
FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia. [More]
AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. [More]
New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society. [More]
Whitehead Institute researchers identify drug target for anemia

Whitehead Institute researchers identify drug target for anemia

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy. [More]

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

PROLOR Biotech, Inc., a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone, in growth hormone deficient adults. [More]
TSRI scientists devise new technique to find therapeutic antibodies

TSRI scientists devise new technique to find therapeutic antibodies

Scientists at The Scripps Research Institute have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world's best-selling medicines, diagnostics and laboratory reagents. [More]

Prior administration of erythropoietin reduces need for blood transfusions

Anemia increases operative mortality and morbidity in non-cardiac and cardiac surgical procedures. Anemic surgical patients may require more blood transfusions, raising the risk of transfusion-related complications and increasing costs. [More]
Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013. [More]
Two studies shed light on molecular biology of three blood disorders

Two studies shed light on molecular biology of three blood disorders

Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases. [More]

Aarbepoetin alfa does not improve anemic heart failure patients' health

Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients -darbepoetin alfa - does not improve patients' health, nor does it reduce their risk of death from heart failure. [More]
Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. [More]
Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS). [More]
Paper says hospitals that do treat patients with anemia have better outcomes

Paper says hospitals that do treat patients with anemia have better outcomes

Up to one-third of patients undergoing surgery in Ontario have a treatable form of anemia but are not optimally treated for it. [More]
NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease. [More]
Medgenics’ EPODURE Biopump technology for EPO delivery receives U.S. patent

Medgenics’ EPODURE Biopump technology for EPO delivery receives U.S. patent

Medgenics, Inc., the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics' EPODURE Biopump technology for delivery of erythropoietin (EPO). [More]

United States Pharmacopeial Convention to host Fifth Bioassay Workshop in Rockville

As a growing number of biologic drugs are treatments of choice for an expanding list of autoimmune disorders, inflammatory diseases, and certain cancers, bioassays play a critical role in establishing the functional integrity and potency of these products. [More]